Underwater Endoscopic Mucosal Resection for small Type I gastric neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center study evaluates underwater endoscopic mucosal resection (UEMR) for small, type I gastric neuroendocrine tumors. The primary outcome is the rate of complete histologic removal with clear margins (R0). Secondary outcomes include en bloc resection rate, immediate and delayed adverse events, procedure time, margin quality, and detection of residual or metachronous disease during follow-up. The study analyzes results at the lesion level while accounting for potential clustering of multiple lesions within the same patient.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient-level

* Age ≥18 years
* Fit for endoscopic therapy and sedation
* Written informed consent

Exclusion Criteria:

Lesion-level

* Endoscopically visible gastric neuroendocrine tumor
* Size 5-9 mm (endoscopic estimation)
* Clinical and/or histologic features consistent with type I gastric NET
* No endoscopic features suggestive of deep invasion
* Technically amenable to snare resection

Where it's running

• Asian Institute of Gastroenterology/AIG Hospitals
  Hyderabad, Telangana, India Recruiting

Study contacts

• Principal investigator: Zaheer Dr Nabi, MD — Aig Hospitals
• Study coordinator: Rajesh Mr Goud, M.Pharmacy
• Email: rajeshgoud761@gmail.com
• Phone: 04023378888

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perianal fistula imaging comparison using TPUS, MRI, EUS, and EUA

  This study tests how well four imaging methods—transperineal ultrasound, MRI, endoscopic ultrasound, and examination under anesthesia—detect and describe perianal fistulas in adults with Crohn's disease or unknown cause.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telanagana · NCT07794410

• Vonoprazan Alone vs With Itopride for Functional Dyspepsia

  This study tests whether adding itopride to vonoprazan helps adults with functional dyspepsia feel better compared with vonoprazan alone.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07731542

• Understanding brain changes in chronic pancreatitis pain

  This study tests whether central nervous system changes and neuropsychological factors help explain persistent pain in adults with chronic pancreatitis.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07707609

• Microbial pancreatic enzyme therapy versus porcine enzyme in chronic pancreatitis with exocrine pancreatic insufficiency

  This study tests whether a microbial (fungal) pancreatic enzyme product can work as well as the standard porcine enzyme in adults with chronic pancreatitis and PEI.

  Recruiting Phase 3 Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07697352

• Composite way to measure treatment success in acute cholangitis with biliary drainage

  This study tests a new composite index to measure how well treatment works for adults with acute cholangitis who undergo biliary drainage.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07667166

• Autologous tSVF Injection for Refractory Perianal Crohn’s Disease

  We’re testing whether injecting a patient’s own mechanically processed tissue stromal vascular fraction around and into fistula tracts can help heal complex perianal Crohn’s disease in people who have not responded to standard therapies.

  Recruiting at 2 sites Asian Institute of Gastroenterology, India · Hyderabad, Telangana and 1 other locations · NCT07652632

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.